VIS-649 is under clinical development by Visterra and currently in Phase II for IgA Nephropathy (Berger’s Disease). According to GlobalData, Phase II drugs for IgA Nephropathy (Berger’s Disease) have a 53% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how VIS-649’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

VIS-649 overview

VIS-649 is under development for the treatment of IgA nephropathy (Berger's disease) and Henoch-schonlein purpura. It is administered through intravenous and subcutaneous routes. The drug candidate is a humanized Ig G2 monoclonal antibody developed based on hierotope technology. It acts by targeting the cytokine, A Proliferation Inducing Ligand (APRIL).

Visterra overview

Visterra, formerly Parasol Therapeutics is a clinical-stage biopharmaceutical company that develops antibody therapies for the treatment of infectious diseases. The company’s pipeline products include VIS410, a monoclonal antibody designed to treat influenza A; VIS513, monoclonal antibody for the treatment of dengue; and VIS649, an anti-APRIL monoclonal antibody (mAb) for the treatment of Imumuglobulin A Nephropathy (IgAN). Visterra utilizes its hierotope platform to design and engineer antibody-based therapies that target specific regions and epitopes of pathogens. The company’s technology is based on the atomic interaction network analysis that supports in identifying hierotopes. Visterra is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of VIS-649’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.